Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2016, Article ID 8395268, 7 pages
http://dx.doi.org/10.1155/2016/8395268
Research Article

Tigecycline Therapy for Nosocomial Pneumonia due to Carbapenem-Resistant Gram-Negative Bacteria in Critically Ill Patients Who Received Inappropriate Initial Antibiotic Treatment: A Retrospective Case Study

1Department of Respiratory Medicine, Taizhou Hospital of Zhejiang Province, Linhai 317000, China
2Operation Department, Taizhou Hospital of Zhejiang Province, Linhai 317000, China

Received 8 August 2016; Revised 9 November 2016; Accepted 14 November 2016

Academic Editor: Paola Di Carlo

Copyright © 2016 Xiaomai Wu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. W. Olson, A. Ruzin, E. Feyfant, T. S. Rush III, J. O'Connell, and P. A. Bradford, “Functional, biophysical, and structural bases for antibacterial activity of tigecycline,” Antimicrobial Agents and Chemotherapy, vol. 50, no. 6, pp. 2156–2166, 2006. View at Publisher · View at Google Scholar · View at Scopus
  2. T. Kelesidis, D. E. Karageorgopoulos, I. Kelesidis, and M. E. Falagas, “Tigecycline for the treatment of multidrug-resistant Enterobacteriaceae: a systematic review of the evidence from microbiological and clinical studies,” Journal of Antimicrobial Chemotherapy, vol. 62, no. 5, pp. 895–904, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. B. Özbek and G. Ötük, “In vitro activities of tigecycline alone and in combination with colistin sulfate or sulbactam against carbapenem-susceptible and -resistant Acinetobacter baumannii strains isolated from Intensive Care Units,” International Journal of Antimicrobial Agents, vol. 36, no. 2, pp. 191–192, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. H. S. Sader, D. J. Farrell, and R. N. Jones, “Tigecycline activity tested against multidrug-resistant Enterobacteriaceae and Acinetobacter spp. isolated in US medical centers (2005–2009),” Diagnostic Microbiology and Infectious Disease, vol. 69, no. 2, pp. 223–227, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. K. B. Waites, L. B. Duffy, and M. J. Dowzicky, “Antimicrobial susceptibility among pathogens collected from hospitalized patients in the United States and in vitro activity of tigecycline, a new glycylcycline antimicrobial,” Antimicrobial Agents and Chemotherapy, vol. 50, no. 10, pp. 3479–3484, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. E. Tasina, A.-B. Haidich, S. Kokkali, and M. Arvanitidou, “Efficacy and safety of tigecycline for the treatment of infectious diseases: a meta-analysis,” The Lancet Infectious Diseases, vol. 11, no. 11, pp. 834–844, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. P. Prasad, J. Sun, R. L. Danner, and C. Natanson, “Excess deaths associated with tigecycline after approval based on noninferiority trials,” Clinical Infectious Diseases, vol. 54, no. 12, pp. 1699–1709, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. P. Montravers, H. Dupont, J.-P. Bedos, and P. Bret, “Tigecycline use in critically ill patients: a multicentre prospective observational study in the intensive care setting,” Intensive Care Medicine, vol. 40, no. 7, pp. 988–997, 2014. View at Publisher · View at Google Scholar · View at Scopus
  9. B. Balandin Moreno, I. Fernández Simón, V. Pintado García et al., “Tigecycline therapy for infections due to carbapenemase-producing Klebsiella pneumoniae in critically ill patients,” Scandinavian Journal of Infectious Diseases, vol. 46, no. 3, pp. 175–180, 2014. View at Publisher · View at Google Scholar · View at Scopus
  10. K. Pontikis, I. Karaiskos, S. Bastani et al., “Outcomes of critically ill intensive care unit patients treated with fosfomycin for infections due to pandrug-resistant and extensively drug-resistant carbapenemase-producing Gram-negative bacteria,” International Journal of Antimicrobial Agents, vol. 43, no. 1, pp. 52–59, 2014. View at Publisher · View at Google Scholar · View at Scopus
  11. M. Bassetti, C. Eckmann, K. F. Bodmann et al., “Prescription behaviours for tigecycline in real-life clinical practice from five European observational studies,” Journal of Antimicrobial Chemotherapy, vol. 68, supplement 2, pp. II5–II14, 2013. View at Publisher · View at Google Scholar · View at Scopus
  12. R. Guner, I. Hasanoglu, S. Keske, A. K. Kalem, and M. A. Tasyaran, “Outcomes in patients infected with carbapenem-resistant Acinetobacter baumannii and treated with tigecycline alone or in combination therapy,” Infection, vol. 39, no. 6, pp. 515–518, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. J. D. Chan, J. A. Graves, and T. H. Dellit, “Antimicrobial treatment and clinical outcomes of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia,” Journal of Intensive Care Medicine, vol. 25, no. 6, pp. 343–348, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. M. K. Joung, K. T. Kwon, C.-I. Kang et al., “Impact of inappropriate antimicrobial therapy on outcome in patients with hospital-acquired pneumonia caused by Acinetobacter baumannii,” Journal of Infection, vol. 61, no. 3, pp. 212–218, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. G. De Pascale, L. Montini, M. A. Pennisi et al., “High dose tigecycline in critically ill patients with severe infections due to multidrug-resistant bacteria,” Critical Care, vol. 18, no. 3, article R90, 2014. View at Publisher · View at Google Scholar · View at Scopus
  16. N. Gupta, B. M. Limbago, J. B. Patel, and A. J. Kallen, “Carbapenem-resistant enterobacteriaceae: epidemiology and prevention,” Clinical Infectious Diseases, vol. 53, no. 1, pp. 60–67, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. R. K. Shields, C. J. Clancy, L. M. Gillis et al., “Epidemiology, clinical characteristics and outcomes of extensively drug-resistant acinetobacter baumannii infections among solid organ transplant recipients,” PLoS ONE, vol. 7, no. 12, article e52349, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. American Thoracic Society, “Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia,” American Journal of Respiratory and Critical Care Medicine, vol. 171, no. 4, pp. 388–416, 2005. View at Publisher · View at Google Scholar
  19. T. Kim, Y. P. Chong, S. Y. Park et al., “Risk factors for hospital-acquired pneumonia caused by carbapenem-resistant Gram-negative bacteria in critically ill patients: a multicenter study in Korea,” Diagnostic Microbiology and Infectious Disease, vol. 78, no. 4, pp. 457–461, 2014. View at Publisher · View at Google Scholar · View at Scopus
  20. D. R. Chung, J.-H. Song, S. H. Kim et al., “High prevalence of multidrug-resistant nonfermenters in hospital-acquired pneumonia in Asia,” American Journal of Respiratory and Critical Care Medicine, vol. 184, no. 12, pp. 1409–1417, 2011. View at Publisher · View at Google Scholar · View at Scopus
  21. M. E. Falagas, P. Lourida, P. Poulikakos, P. I. Rafailidis, and G. S. Tansarli, “Antibiotic treatment of infections due to carbapenem-resistant enterobacteriaceae: systematic evaluation of the available evidence,” Antimicrobial Agents and Chemotherapy, vol. 58, no. 2, pp. 654–663, 2014. View at Publisher · View at Google Scholar · View at Scopus
  22. J. J. Schafer, D. A. Goff, K. B. Stevenson, and J. E. Mangino, “Early experience with tigecycline for ventilator-associated pneumonia and bacteremia caused by multidrug-resistant Acinetobacter baumannii,” Pharmacotherapy, vol. 27, no. 7, pp. 980–987, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. A. T. Freire, V. Melnyk, M. J. Kim et al., “Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia,” Diagnostic Microbiology and Infectious Disease, vol. 68, no. 2, pp. 140–151, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. W. Kim, J. Moon, J. W. Huh et al., “Comparable efficacy of tigecycline versus colistin therapy for multidrug-resistant and extensively drug-resistant Acinetobacter baumannii pneumonia in critically Ill patients,” PLoS ONE, vol. 11, no. 3, article e0150642, 2016. View at Publisher · View at Google Scholar
  25. S. M. Bhavnani, C. M. Rubino, J. P. Hammel et al., “Pharmacological and patient-specific response determinants in patients with hospital-acquired pneumonia treated with tigecycline,” Antimicrobial Agents and Chemotherapy, vol. 56, no. 2, pp. 1065–1072, 2012. View at Publisher · View at Google Scholar · View at Scopus
  26. P. C. McGovern, M. Wible, A. El-Tahtawy, P. Biswas, and R. D. Meyer, “All-cause mortality imbalance in the tigecycline phase 3 and 4 clinical trials,” International Journal of Antimicrobial Agents, vol. 41, no. 5, pp. 463–467, 2013. View at Publisher · View at Google Scholar · View at Scopus